A Phase I study of adjuvant chemotherapy with gemcitabine plus S-1 in patients with biliary tract cancer undergoing curative resection without major hepatectomy.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 14 Sep 2016
At a glance
- Drugs Gemcitabine (Primary) ; Gimeracil/oteracil/tegafur (Primary)
- Indications Biliary cancer
- Focus Adverse reactions
- 31 Aug 2016 Status changed from recruiting to active, no longer recruiting.
- 22 Oct 2012 Planned end date (Mar 2017) added as reported by ClinicalTrials.gov.
- 22 Oct 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01713387).